Loading
CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.
ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression.
IntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Gastrointestinal Stromal Tumour, Papillary Renal Cell Carcinoma.
In plain words · CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.
CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.
ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3.
No product in this corpus aims at CHD2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1997. Earliest sequence paper UniProt cites for the protein: Woodage et al, Proc. Natl. Acad. Sci. U.S.A, 1997, "Characterization of the CHD family of proteins". Source.
Sources: HGNC HGNC:1917 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14647 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000173575 (per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.72, B-cell chronic lymphocytic leukaemia 0.71, non-Hodgkin lymphoma 0.72, leukaemia 0.74 (GraphQL API, CC0)); IntOGen CHD2 (driver in 7 cohorts (Act 3, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression. Location: Nucleus (UniProt). Locus 15q26.1 (HGNC).
Query for this target: (TITLE:"CHD2" OR ABSTRACT:"CHD2" OR TITLE:"chromodomain helicase DNA binding protein 2" OR ABSTRACT:"chromodomain helicase DNA binding protein 2" OR TITLE:"ATP-dependent chromatin remodeler CHD2" OR ABSTRACT:"ATP-dependent chromatin remodeler CHD2" OR TITLE:"FLJ38614" OR ABSTRACT:"FLJ38614" OR TITLE:"DKFZp547I1315" OR ABSTRACT:"DKFZp547I1315" OR TITLE:"DKFZp781D1727" OR ABSTRACT:"DKFZp781D1727") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CHD2, not a curated reading list.
Shares Papillary renal cell carcinoma, Leukaemia (all types), Renal cell carcinoma, Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, IntOGen.
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).